This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Eifel PJ et al. (2004) Pelvic irradiation therapy with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer. J Clin Oncol 22: 872–880
Morris M et al. (1999) Pelvic radiation with concurrent chemotherapy versus pelvic and para-aortic radiation for high risk cervical cancer: a randomized Radiation Therapy Oncology Group clinical trial. N Engl J Med 340: 1137–1143
Rose PG et al. (2007) Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group study. J Clin Oncol 25: 2804–2810
Acknowledgements
The synopsis was written by Mandy Aujla, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Rades, D., Schild, S. Cisplatin alone or in combination versus hydroxyurea during pelvic irradiation for cervical cancer. Nat Rev Clin Oncol 5, 128–129 (2008). https://doi.org/10.1038/ncponc1017
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncponc1017